<?xml version="1.0" encoding="UTF-8"?>
<p>Bornyl salicylate—commonly known salicylic derivative, obtained by esterification of salicylic acid and (–)-borneol in the early 20th century—was used topically in inflammatory diseases. Interestingly, it was only in 2012 that the first detailed analysis of the anti-inflammatory effects of bornyl salicylate (BS) in experimental models of acute inflammation was done [
 <xref rid="B104-ijms-21-07078" ref-type="bibr">104</xref>]. That research showed that signs of acute toxicity are not observed either in male or female mice. The authors revealed that the tested pharmaceutical compound is anti-inflammatory, which is related to the decrease in pro-inflammatory mediators because the treatment with bornyl salicylate is effective in the reduction of paw edema in both early and late phases.
</p>
